These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?].
    Author: Ruiz de la Roja JC, Llorente Abarca C, Romero Cagigal I, Páez Borda A, Fernández González I, Martín Osés E, Berenguer Sánchez A.
    Journal: Actas Urol Esp; 1995 Feb; 19(2):123-7. PubMed ID: 7539572.
    Abstract:
    Since the discovery of the prostate specific antigen, and its use as tumoral marker, not only this has been shown to have a significant application for the diagnosis and evaluation of prostate cancer management, but also to be an eventual help to predict occurrence of bone metastasis. A retrospective study was conducted in 50 patient with prostate cancer, with mean age of 74 years (range 56-90), where PSA levels were analyzed and then correlated with the results obtained with bone scintigraphy. Our work results were that, given a 40% prevalence of the metastatic disease, no patient had PSA values under 10 ng/ml and, at the same time, bone dissemination, i.e., a 100% negative predictive value. Thus, we can state that in our group, we could have given a PSA cut-off value over 10 ng/ml to perform bone scintigraphy, without making any staging mistake.
    [Abstract] [Full Text] [Related] [New Search]